Transcutaneous Electrical Acupoint Stimulation (TEAS) for Chronic Constipation

NCT ID: NCT03243955

Last Updated: 2023-10-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-28
• Study Completion Date: 2026-03-01

Brief Summary

Transcutaneous electrical acupoint stimulation (TEAS) is an emerging technology for non-invasive neuromodulation that has broad potential implications and warrants further study. The investigators' clinical experience from the University of California, Los Angeles (UCLA) Center for East-West Medicine (CEWM) has also demonstrated that TEAS can be used as an effective self-care tool for patients with chronic illness who do not have the time or resources for frequent acupuncture treatments. Chronic constipation is the chosen area of study because of the large population with a substantial impairment in health-related quality of life and work productivity. The investigators have recently completed a randomized controlled trial (RCT) demonstrating the benefit of perineal self-acupressure on quality of life measurements in this population, which supports investigation into other acupuncture-based self-care interventions. Given these findings, the investigators hypothesize that home patient-administered TEAS can provide measurable improvements in both symptom severity and health related quality of life.

Detailed Description

This study will be a double blinded randomized controlled trial. Respondents will be screened by phone and qualified subjects will be sent home for 2 weeks to complete a bowel movement logbook, then return into the CEWM office where they will submit validated surveys (specifically, the PAC-SYM and PAC-QOL) and have a photo taken of their tongue. A baseline non-invasive heart rate variability (HRV) measurement will be taken at this time as well. Study personnel will instruct each subject on TEAS pad placement and how to use the device, but not tell the subjects where to place the pads. The subjects will been assigned to one of two experimental groups (verum and sham) based on a 1:1 random allocation, with the study personnel blinded to the allocation. Both groups will be given transcutaneous electrical nerve stimulator (TENS) units with pre-set parameters and access to the adjustable amplitude dial for self-adjustment of amplitude, with the verum group given pre-printed information on proper application on true acupoints, and sham group will be given information on non-acupuncture points. The subjects will be instructed on daily use for 30 minutes per day for at least 5 days per week, and asked to track device use as well as bowel movement frequency and quality using a logbook. They will also submit to an online survey every week during the 4-week trial period. At the conclusion of the study, they will return the units and repeat the survey and HRV measurements.

Conditions

Constipation - Functional

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

TEAS

True acupoint locations for placement of TENS unit pads

Group Type: ACTIVE_COMPARATOR

Verum TEAS

Intervention Type: DEVICE

TENS unit with electrodes applied to acupuncture point locations

Placebo

non-acupoint locations for placement of TENS unit pads

Group Type: SHAM_COMPARATOR

Sham TEAS

Intervention Type: DEVICE

TENS unit with electrodes applied to non-acupuncture point locations

Interventions

Verum TEAS

TENS unit with electrodes applied to acupuncture point locations

Intervention Type: DEVICE

Sham TEAS

TENS unit with electrodes applied to non-acupuncture point locations

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 18 years of age or older
• Satisfy a modified ROME-IV criteria for functional constipation including:

• Fewer than three spontaneous bowel movements per week
• and meet one of the following symptoms for at least 12 weeks in the preceding 12 months:

• straining during >25% of the bowel movements (BMs)
• lumpy or hard stools during >25% of BMs
• sensation of incomplete evacuation during >25% of BMs
• sensation of anorectal obstruction or blockage for >25% of BMs
• manual maneuvers to facilitate >25% of BMs
• loose stools are rarely present without the use of laxatives
• insufficient criteria for IBS (does not have recurrent abdominal pain at least 1 day per week in the past 3 months)
• able to understand and provide written consent
• If over age 50, have undergone routine colon cancer screening (colonoscopy, sigmoidoscopy, colonography or fecal occult blood testing)
• subjects must have normal serum chemistry and normal thyroid stimulating hormone (TSH) within the past year
• subjects must have normal sensation over the areas where the pads will be placed (lumbar region and lower extremities surrounding the knees anteriorly)

Exclusion Criteria

• Pregnancy
• Numbness around the genitals or groin, bladder or bowel dysfunction or incontinence, new sciatica type leg pain or new onset sexual dysfunction within the past year.
• Any changes to constipation related medications over the past 1 month
• Use of rescue medication (polyethylene glycol, bisacodyl, enema, etc) greater than once per week
• Pacemaker, implanted cardiac defibrillator or other implanted electrical device
• 10% weight loss in past 6 months
• New onset Hematochezia since last medical evaluation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of California, Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Andrew Shubov, MD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Andrew Shubov, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

University of California, Los Angeles

Los Angeles, California, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Andrew Shubov, MD

Role: CONTACT

ashubov@mednet.ucla.edu

310-998-9118

Facility Contacts

Andrew Shubov, MD

Role: primary

ashubov@mednet.ucla.edu

310-998-9118

Other Identifiers

441356-KH-50890

Identifier Type: -

Identifier Source: org_study_id